(S)-(+)-4-Methyl-1-hexanol
| Common Name: |
(S)-(+)-4-Methyl-1-hexanol |
| IUPAC Name: |
(4S)-4-methylhexan-1-ol |
| Molecular Formula: |
C12H24O3 |
| SMILES: |
CCC(C)CCCO |
| Inchi: |
1S/C7H16O/c1-3-7(2)5-4-6-8/h7-8H,3-6H2,1-2H3/t7-/m0/s1 |
| Inchi Key: |
YNPVNLWKVZZBTM-ZETCQYMHSA-N |
| Cas No: |
1767-46-0 |
| Name |
Value |
| Lipinski Violations |
0 |
| Ghose Violations |
0 |
| Veber Violations |
0 |
| Egan Violations |
0 |
| Muegge Violations |
0 |
| Name |
Value |
| Molecular Weight (g/mol) |
216.32 |
| Mass (g/mol) |
116.12 |
| Molar Refractivity |
62.24 |
| Net Charge |
|
| HBD |
1 |
| HBA |
3 |
| Rt Bonds |
10 |
| Rings |
|
| TPSA |
46.53 |
| Hetero Atoms |
1 |
| Heavy Atoms |
15 |
| Aromatic Heavy Atoms |
0 |
| Melting Point (°C) |
|
| Boiling Point (°C@760.00mm Hg) |
173.00 |
| Vapor Pressure (mmHg@25.00 °C) |
0.4 |
| Vapor Density (Air =1) |
|
| Fraction Csp3 |
0.92 |
| LogP |
1.805 |
| iLOGP |
3.27 |
| XLOGP3 |
2.85 |
| WLOGP |
2.66 |
| MLOGP |
2.27 |
| ESOL Log S |
-2.32 |
| ESOL Solubility (mg/ml) |
1.04 |
| ESOL Solubility (mol/l) |
0.005 |
| ESOL Class: esol_class |
Soluble |
| Ali Log S |
-3.49 |
| Ali Solubility (mg/ml) |
0.07 |
| Ali Solubility (mol/l) |
0 |
| Ali Class |
Soluble |
| Silicos-IT LogSw |
-3.06 |
| Silicos-IT Solubility (mg/ml) |
0.19 |
| Silicos-IT Solubility (mol/l) |
0 |
| Silicos-IT Class |
Soluble |
| Name |
Value |
| GI Absorption |
High |
| BBB Permeable |
1 |
| PgP Substrate |
0 |
| Log Kp (cm/s) |
-5.60 |
| Bioavailability Score |
0.55 |
| Caco2 |
1 |
| Human Intestinal Absorption |
1 |
| Plasm Protein Binding |
1.03 |
| CYP1A2 Inhibitor |
0 |
| CYP2C19 Inhibitor |
0 |
| CYP2C9 Inhibitor |
0 |
| CYP2D6 inhibitor |
0 |
| CYP3A4 inhibitor |
0 |
| Ames mutagenesis |
0 |
| Acute Oral Toxicity |
2.054 |
| Carcinogenicity (Binary) |
0 |
| Carcinogenicity (Trinary) |
Non-required |
| Eye Irritation |
1 |
| Hepatotoxicity |
0 |
| Androgen Receptor Binding |
0 |
| Aromatase Binding |
0 |
| Estrogen Receptor Binding |
0 |
| Glucocorticoid Receptor Binding |
0 |
| Thyroid Receptor Binding |
0 |
| BRCP inhibitor |
0 |
| BSEP inhibitor |
0 |
| OATP1B1 inhibitor |
1 |
| OATP1B3 inhibitor |
1 |
| OATP2B1 inhibitor |
0 |
| OCT1 inhibitor |
0 |
| OCT2 inhibitor |
0 |
